Chimeric Therapeutics Limited · ASX:CHM
Chimeric Therapeutics — Shareholder Meeting (December 2024)
11 slides from Chimeric Therapeutics's shareholder meeting presentation, Dec 4, 2024
Slide 1: Extraordinary General Meeting 2024
For personal use only CHIMERIC CHIMERIC THERAPEUTICS PIONEERS IN CELL THERAPY Extraordinary General Meeting | 2024 ASX: CHM 20 24 CHIMERICTHERAPEUTICS.COM
Slide 2: Disclaimer
2 DEC 2024 | DISCLAIMER For personal use only Certain statements contained in this presentation, applicable regulatory authorities may ask for additional including, without limitation, statements containing the data, information or studies to be completed or provided words “believes,” “plans,” “expe
Slide 3: CHM is a cancer cell therapy company with 3 CAR T & NK cell assets
DEC 2024 | 3 For personal use only ASX:CHM CHIMERIC THERAPEUTICS CHM is a cancer cell therapy company with 3 CAR T & NK cell assets in 4 Phase 1/1b clinical trials CHIMERICTHERAPEUTICS.COM
Slide 4: CAR-T Cell Therapy Explained
DEC 2024 | 4 CAR-T CELL THERAPY EXPLAINED Use a patients own blood cells to make their individualised cancer therapy For personal use only CHIMERIC THERAPEUTICS Laboratory Individual therapy engineering manufactured Leukapheresis (blood draw) Infusion into from individual patient individual patient
Slide 5: CHM: Broad Portfolio of Novel Cell Therapies; Clinical Trials
DEC 2024 | 5 CHM: BROAD PORTFOLIO 3 Novel cell therapies; 4 Clinical Trials For personal use only CHM CDH17 CHM CLTX CHM CORE-NK CHIMERIC THERAPEUTICS CAR-T CAR-T ‘OFF THE SHELF’ NK Technology from: Technology from: Technology from: Phase 1A completed: COH PHASE 1B PHASE 1B PHASE 1/2 TRIAL OPEN PHAS
Slide 6: CHM CORE NK + SOC: Complete response in high risk blood cancer
DEC 2024 | 6 CHM CORE NK + SOC Ongoing Complete response in high risk blood cancer 48months durability COMPLETE For personal use only PATIENT #8 RESPONSE 33-year-old female CORE NK INFUSION CHIMERIC THERAPEUTICS DAY 100 SITE: MDACC Enabling patient to Patient Doses undergo transplant DIAGNOSIS: Myel
Slide 7: CHM CORE NK Combination Trial
DEC 2024 | 7 CHM CORE NK COMBINATION TRIAL Complete response in high risk blood cancer combination trial For personal use only PATIENT #3 female CORE NK INFUSION + TGF-B CHIMERIC THERAPEUTICS SITE: Case Western Day 1 DIAGNOSIS: Actue Myeloid Dysplastic Syndrome SAFETY: No dose limiting toxicities, n
Slide 8: Multiple Clinical Catalysts in the Next 12 Months
DEC 2024 | 8 MULTIPLE CLINICAL CATALYSTS IN THE NEXT 12MTHS 2023 Achievements and Deliverables in 2024 2023 Achievements 2024 Deliverables For personal use only ✓ Ph. 1/2 Site Open CHM CDH17 ✓ FDA IND Clearance for Ph. 1/2 Trial ✓ 1st patient dosed CHIMERIC THERAPEUTICS CHM 2101 • 1st dose co-hort c
Slide 9: CHM Leadership Team
DEC 2024 | 9 CHM LEADERSHIP TEAM EXPERTS IN CELL THERAPY DEVELOPMENT & COMMERCIALISATION For personal use only CHIMERIC THERAPEUTICS Dr Rebecca McQUALTER Dr Jason LITTEN Dr Stephanie ASTROW Chief Executive Officer Chief Medical Officer Chief Scientific Officer 75+ 50+ 5/6 EXPERIENCE EXPERTISE RESULT
Slide 10: Investment Highlights and Corporate Profile
DEC 2024 | 10 INVESTMENT HIGHLIGHTS 4 4 Phase 1 clinical trials For personal use only under 3 FDA INDs at 4 leading US centres CORPORATE PROFILE Multiple clinical updates ASX: CHM CHIMERIC THERAPEUTICS in the next 12mths Exchange Share Price $0.010 Experienced leadership team in cell therapy clinica
Slide 11: Pioneers in Cell Therapy
For personal use only CHIMERIC CHIMERIC THERAPEUTICS PIONEERS IN CELL THERAPY Dr Rebecca McQualter Chief Executive Officer Chimeric Therapeutics Ltd Melbourne, Australia Tel: 03 9864 4809 investors@chimerictherapeutics.com 20 24 CHIMERICTHERAPEUTICS.COM
Chimeric Therapeutics — Shareholder Meeting (December 2024) on 6ix